A mother in critical condition is being denied access to a potentially life-saving drug that could have extended her life to witness her daughter’s prom. Jess Duggan, 44, is advocating for the availability of the Enhertu drug on the NHS to provide crucial additional time for terminally ill mothers to spend with their children. She expressed urgency in her plea to the drug manufacturers and government officials, highlighting the pressing need for families in such dire situations.
Despite being available in Scotland and several European countries, the Enhertu drug is inaccessible to Jess and numerous other women battling breast cancer in England, Wales, and Northern Ireland. Facing a limited time frame, Jess, a mother of two from Lewes, East Sussex, stressed the importance of moments she could share with her husband and children, aged 12 and 15, before her health deteriorates further.
Describing her current situation as a race against time, Jess lamented the absence of the drug that might have provided her with a chance for more quality time with her family. Breast Cancer Now is advocating for immediate action following alterations in NHS drug spending regulations, aiming to secure approval for the life-prolonging treatment Enhertu.
Initially diagnosed with breast cancer in 2017, Jess underwent various treatments to combat the disease, enjoying a few years of remission before the cancer resurfaced aggressively in 2023. Despite undergoing different therapies, including a recent trial, Jess’s condition has worsened, with the cancer spreading to critical organs.
Expressing frustration over the unavailability of the drug, Jess emphasized the value of Enhertu in potentially offering more time to patients facing similar battles. Breast Cancer Now, through its campaign “Enhertu Now,” is urging pharmaceutical companies and healthcare authorities to expedite the approval process for Enhertu to benefit those in urgent need of the treatment.
With mounting public support, the petition for making Enhertu accessible has garnered over 53,000 signatures within a short period, underscoring the significance of the drug in the eyes of the community. Efforts are underway to reach a consensus among stakeholders to ensure timely access to Enhertu for metastatic breast cancer patients, reflecting the critical nature of the situation and the pressing need for decisive action.
